Ascorbate and Hyperphagia - a phase IV clinical study of FDA data
Summary:
We study 37,032 people who take Ascorbate (vitamin c (ascorbic acid)) or have Hyperphagia. No report of Hyperphagia is found in people who take Ascorbate.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Ascorbate?
Ascorbate has active ingredients of vitamin c (ascorbic acid). eHealthMe is studying from 1,446 Ascorbate users. Check the latest studies of Ascorbate.
What is Hyperphagia?
Hyperphagia (an abnormal appetite for food) is found to be associated with 2,208 drugs and 1,975 conditions by eHealthMe. Check the latest studies of Hyperphagia.
No report is found.
Do you take Ascorbate and have Hyperphagia?
- Check whether Hyperphagia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Ascorbate:
- Ascorbate (1,446 reports)
Hyperphagia treatments and more:
- Hyperphagia (35,586 reports)
How severe was Hyperphagia and when was it recovered:
Expand to all the drugs that have ingredients of vitamin c (ascorbic acid):
Browse all side effects of Ascorbate:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Hyperphagia:
Browse all the conditions that are associated with Hyperphagia:
How the study uses the data?
The study uses data from the FDA. It is based on vitamin c (ascorbic acid) (the active ingredients of Ascorbate) and Ascorbate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Zioptan vs. Vyzulta, side effect and effectiveness comparison - now
- Meclizine and Gastric Ulcer for Women aged 60+ - 2 seconds ago
- Meclizine and Peptic Ulcer for Women aged 60+ - 2 seconds ago
- Meclizine and Ulcer - Peptic for Women aged 60+ - 2 seconds ago
- Meclizine and Ulcer - Duodenal Or Gastric for Women aged 60+ - 3 seconds ago
- Meclizine and Duodenal Ulcer for Women aged 60+ - 3 seconds ago
- Drug interactions of Clopidogrel and Tradjenta - 3 seconds ago
- Meclizine and Ulcer for Women aged 60+ - 3 seconds ago
- Meclizine and Ulcer - Stomach for Women aged 60+ - 4 seconds ago
- Meclizine and Stomach Ulcer for Women aged 60+ - 4 seconds ago